1. ScholarBank@NUS

Wee Joo Chng

rp04705

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
Wee Joo Chng
Variants
Chng W.J
Chng, W.J.
Chng W.-J.
Wee Joo Chng
Chng, W.-J.
 
Main Affiliation
 
Faculty
 
Email
mdccwj@nus.edu.sg
 
Other emails
 

Publications

Refined By:
File Format:  Adobe PDF
Type:  Article
Subject:  Article

Results 1-14 of 14 (Search time: 0.023 seconds).

Issue DateTitleAuthor(s)
12018A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphataseZhou, J ; Toh, S.H.-M; Chan, Z.-L; Quah, J.Y; Chooi, J.-Y ; Tan, T.Z ; Chong, P.S.Y ; Zeng, Q ; Chng, W.-J 
22016Aberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomasHirpara, J.L ; Loh, T ; Ng, S.B ; Chng, W.J ; Pervaiz, S 
3Jul-2017Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinomaKong, L.R ; Tan, T.Z ; Ong, W.R; Bi, C; Huynh, H ; Lee, S.C ; Chng, W.J ; Eichhorn, P.J.A ; Goh, B.C 
42018Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myelomaShanmugam, M.K ; Ahn, K.S; Lee, J.H; Kannaiyan, R; Mustafa, N ; Manu, K.A ; Siveen, K.S ; Sethi, G ; Chng, W.J ; Kumar, A.P 
52016Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: A role for MARCKS in acquired resistance to proteasome inhibitorsFranke, N.E; Kaspers, G.L; Assaraf, Y.G; Meerloo, J; Niewerth, D; Kessler, F.L; Poddighe, P.J; Kole, J; Smeets, S.J; Ylstra, B; Bi, C; Chng, W.J ; Horton, T.M; Menezes, R.X; Musters, R.J.P; Zweegman, S; Jansen, G; Cloos, J
62015Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myelomaBi, C; Chung, T.-H ; Huang, G ; Zhou, J ; Yan, J ; Ahmann, G.J; Fonseca, R; Chng, W.J 
72017Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemiaZhou, J ; Bi, C; Ching, Y.Q ; Chooi, J.-Y ; Lu, X; Quah, J.Y ; Toh, S.H.-M ; Chan, Z.-L; Tan, T.Z ; Chong, P.S ; Chng, W.-J 
82018LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL)Hee, Y.T; Yan, J ; Nizetic, D; Chng, W.-J 
92018Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimensRassidakis, G.Z; Herold, N; Myrberg, I.H; Tsesmetzis, N; Rudd, S.G; Henter, J.-I; Schaller, T; Ng, S.-B ; Chng, W.J ; Yan, B; Ng, C.H ; Ravandi, F; Andreeff, M; Kantarjian, H.M; Medeiros, L.J; Xagoraris, I; Khoury, J.D
102015Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyGupta, N; Goh, Y.T ; Min, C.-K; Lee, J.H; Kim, K; Wong, R.S.M; Chim, C.S; Hanley, M.J; Yang, H; Venkatakrishnan, K; Hui, A.-M; Esseltine, D.-L; Chng, W.J 
112018Preleukemic and second-hit mutational events in an acute myeloid leukemia patient with a novel germline RUNX1 mutationNg, I.K.S; Lee, J; Ng, C; Kosmo, B; Chiu, L; Seah, E; Mok, M.M.H ; Tan, K; Osato, M ; Chng, W.-J ; Yan, B; Tan, L.K 
122016PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylationTeoh P.J. ; Bi C.; Sintosebastian C.; Tay L.S. ; Fonseca R.; Chng W.J. 
132015PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanismsLi, X.-L; Zhou, J ; Chan, Z.-L; Chooi, J.-Y ; Chen, Z.-R; Chng, W.-J 
142017VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of BimMustafa, N ; Ting Lee, J.X ; Adina Nee, H.F ; Bi, C; Chung, T.-H ; Hart, S; Chng, W.J